[
  {
    "ts": null,
    "headline": "Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations. The data were presented at the World Conference on Lung Cancer (WCLC). At this year’s WCLC, five-year efficacy",
    "url": "https://finnhub.io/api/news?id=f76b4a1fafc940213deab9ec5d8dc9a7922c3c42a39ab1277f3137e617ec28dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757448604,
      "headline": "Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy",
      "id": 136689964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo (cemiplimab) plus platinum-based chemotherapy versus chemotherapy alone as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations. The data were presented at the World Conference on Lung Cancer (WCLC). At this year’s WCLC, five-year efficacy",
      "url": "https://finnhub.io/api/news?id=f76b4a1fafc940213deab9ec5d8dc9a7922c3c42a39ab1277f3137e617ec28dc"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s cat and birch allergy mAbs score in Phase III trials",
    "summary": "These readouts will help structure the confirmatory trials for the two allergy combination therapies.",
    "url": "https://finnhub.io/api/news?id=b6268f8798228fb869fec7339796fb7cdf0146002ee3e4e7a0a919bfdfbdb724",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757439501,
      "headline": "Regeneron’s cat and birch allergy mAbs score in Phase III trials",
      "id": 136689965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "These readouts will help structure the confirmatory trials for the two allergy combination therapies.",
      "url": "https://finnhub.io/api/news?id=b6268f8798228fb869fec7339796fb7cdf0146002ee3e4e7a0a919bfdfbdb724"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "0409 ET – Novartis’s $1.4 billion deal to buy Tourmaline Bio looks like a strategically meaningful move that is set to complement its cardiovascular-treatment pipeline, Vontobel analyst  Stefan Schneider  writes.  The deal makes sense for the Swiss pharmaceutical group as it bolsters the company’s franchise catering to cardiovascular patients with underserved needs, specifically anti-inflammatory therapies, Schneider adds.  Tourmaline Bio is a U.S. biopharmaceutical company developing pacibekitug, a promising treatment candidate for clogged heart and blood vessels in advanced phase 2 trials.",
    "url": "https://finnhub.io/api/news?id=fab193060145f34cadd8d6b6ea037daf8f71da490389d94c2302c84e81edc6fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757438880,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136689966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "0409 ET – Novartis’s $1.4 billion deal to buy Tourmaline Bio looks like a strategically meaningful move that is set to complement its cardiovascular-treatment pipeline, Vontobel analyst  Stefan Schneider  writes.  The deal makes sense for the Swiss pharmaceutical group as it bolsters the company’s franchise catering to cardiovascular patients with underserved needs, specifically anti-inflammatory therapies, Schneider adds.  Tourmaline Bio is a U.S. biopharmaceutical company developing pacibekitug, a promising treatment candidate for clogged heart and blood vessels in advanced phase 2 trials.",
      "url": "https://finnhub.io/api/news?id=fab193060145f34cadd8d6b6ea037daf8f71da490389d94c2302c84e81edc6fa"
    }
  },
  {
    "ts": null,
    "headline": "Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer",
    "summary": "Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months TARRYTOWN, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announ",
    "url": "https://finnhub.io/api/news?id=f553fbe3717f7f81e612430ec58c3d2a7f427c183bd30edff83e0f769e7f0f48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757419200,
      "headline": "Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer",
      "id": 136689967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months TARRYTOWN, N.Y., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announ",
      "url": "https://finnhub.io/api/news?id=f553fbe3717f7f81e612430ec58c3d2a7f427c183bd30edff83e0f769e7f0f48"
    }
  }
]